---
company: Solventum Corp
ticker: SOLV
form: 8-K
filed: 2026-08-05
accession: 0001964738-26-000045
source: https://www.sec.gov/Archives/edgar/data/1964738/000196473826000045/
---

# Solventum (SOLV) earnings release, August 5, 2026

Solventum Corp (SOLV) · Form 8-K, Item 2.02 · Filed 2026-08-05 · [SEC filing](https://www.sec.gov/Archives/edgar/data/1964738/000196473826000045/)

Solventum Reports Second Quarter 2026 Financial Results

• R eported sales increased 2.2%; organic sales increased 9.5%

• Announces intent to separate its Health Information Systems business segment

• Increases full-year 2026 guidance for organic sales growth, adjusted EPS and free cash flow

EAGAN, Minn., August 5, 2026 – Solventum (NYSE: SOLV) today reported financial results for the second quarter ended June 30, 2026.

Second Quarter 2026 Highlights

• S ales of $2.2 billion, increased 2.2% on a reported basis; an increase of 9.5% on an organic basis

• G

AAP diluted earnings per share of $0.53; adjusted diluted earnings per share of $2.55, a 50.9% increase

• Operating cash flow of $227 million; free cash flow of $144 million

“The Solventum team delivered another quarter of strong execution with results ahead of our expectations while continuing to advance our transformation,” said Bryan Hanson, chief executive officer of Solventum. “We remain on track to achieve our long-term objectives as we build a more focused, dedicated MedTech company, well-positioned to create long-term shareholder value.”

Second Quarter and First Six Months 2026 Financial Results¹

Represents non-GAAP financial measure; see the “Non-GAAP Financial Measures” section for applicable information.

Discussion of Second Quarter Results

All comparisons are to the prior year period unless otherwise noted

• Organic sales growth of +

9.5% in the quarter reflects strong performance across all reportable segments, primarily driven by volume and product mix and including the expected benefit of advance orders placed ahead of ERP cutovers.

• GAAP and adjusted gross margin both increased, driven by IEEPA tariff refund.

• GAAP selling, general and administrative expenses increased primarily due to higher costs associated with separation activities and net legal costs. Adjusted SG&A as a percent of sales was 26.0%, a decrease of 130 bps vs. prior year.

• GAAP operating income margin decreased, primarily driven by net legal costs, separation and restructuring costs. Adjusted operating income margin increased primarily due to a combination of IEEPA tariff refund and ERP-timing benefit.

• Operating cash flow for the quarter was

$227 million and free cash flow was

$144 million, ahead of expectations driven by timing of tax payments and insurance proceeds.¹

Other Business and Operational Highlights

• Announced the intent to separate its Health Information Systems business segment as part of the portfolio optimization phase of its transformation strategy. The proposed separation is expected to strengthen Solventum’s focus as a dedicated MedTech company while enabling both businesses to pursue distinct growth and innovation priorities.

• The Solventum Foundation announced a $350,000 grant to America’s ToothFairy to expand access to oral health screenings, dental education and fluoride treatment for more than 100,000 children and caregivers in underserved communities over the next year.

• For the second year in a row, named a

Best Company to Work For by U.S. News & World Report in the categories of ‘Health Care and Research’ and ‘Midwest.’

*Data in the schedule above is intentionally rounded to the nearest million and, therefore, may not sum. “NM” reflects results considered not meaningful due to sale of the Purification and Filtration business in September 2025.²

Constant currency represents the change in net sales absent the impact on sales from foreign currency translation.³

Other represents sales impact from acquisitions and divestitures measured separately for the first 12 months post-transaction. Acquisitions include sales from the December 2025 acquisition of Acera. Divestitures primarily represents lost sales from the Company’s Purification and Filtration business that was sold in September 2025.⁴

All Other includes the Drinking Water business, which was previously reported within Purification and Filtration, and sales related to product supplied to 3M and other supply agreements related to legacy 3M business and assumed by the Company at Spin-Off.²

Full-Year 2026 Guidance

Solventum is updating its full year 2026 guidance as follows:

• Increased organic sales growth range to +2.5% to +3.0% (+3.5% to +4.0% excluding ~100 bps of SKU exit impact); from prior range of +2.0% to +3.0%

• Increased adjusted EPS range to $7.10 to $7.20; from the upper end of prior range of $6.40 to $6.60

• Increased free cash flow to be in the range of $200 million to $300 million; from prior estimate of ~$200M

Organic sales, adjusted diluted EPS and free cash flow amounts included in Solventum’s full-year guidance are non-GAAP financial measures. Solventum does not provide reconciliations of the forward-looking non-GAAP financial measures to the respective GAAP metrics as it is unable to predict with reasonable certainty and without unreasonable effort certain items, such as the impact of changes in currency exchange rates, impacts associated with business acquisitions or divestitures, and the timing and magnitude of restructuring activities, among other items.

See the “Non-GAAP Financial Measures” section for explanations of our non-GAAP financial measures.

Earnings Conference Call

Solventum will host a conference call today, August 5, at 4:30 p.m. Eastern Time to discuss its second quarter financial results and fiscal year 2026 outlook. The conference call can be accessed via audio webcast at investors.solventum.com or by dialing (800) 715-9871 within the U.S. or +1 (646) 307-1963 for international callers, using the conference ID 6342275.

A replay of the webcast, along with the earnings press release, slides highlighting the results and supplemental financial disclosures, will also be available at the same link on the Investor Relations section of the Company’s website.

Forward-Looking Statements... (truncated)1995, Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934 that are subject to risks and uncertainties. Solventum intends the forward-looking statements to be covered by the safe harbor provisions for forward-looking statements in those sections. Forward-looking statements include all statements that are not historical facts, but instead represent only Solventum’s beliefs regarding future goals, plans and expectations about its prospects for the future and other events, many of which, by their nature, are inherently uncertain and outside of Solventum’s control. Forward-looking statements include those containing such words as “anticipates,” “believes,” “can,” “continue,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “guidance,” “intends,” “may,” “outlook,” “plans,” “potential,” “predicts,” “projects,” “seeks,” “sees,” “should,” “targets,” “will,” “would,” or other words of similar meaning in connection with any discussion of future operating or financial performance, business plans or prospects, Solventum’s review of strategic alternatives for its health information systems business, or the potential benefits of any such strategic alternatives or transaction.

Among the factors that could cause actual results to differ materially from those described in our forward-looking statements are the following: (1) whether Solventum will be able to identify or develop any strategic alternatives for Solventum’s health information systems business; (2) Solventum’s ability to execute on material aspects of any strategic alternatives that are identified and pursued; (3) whether Solventum can actually achieve the potential benefits of any strategic alternatives; (4) the occurrence of any event, change or other circumstances that could give rise to the abandonment of the review of strategic alternatives or pursuit of a different structure or strategic alternative; (5) uncertainties as to the timing of the review of strategic alternatives; (6) the effects of, and changes in, worldwide economic, political, regulatory, international, trade and geopolitical conditions, natural disasters, war, public health crises and other events beyond Solventum’s control; (7) operational execution risks; (8) damage to Solventum’s reputation or its brands; (9) risks from acquisitions, strategic alliances, divestitures and other strategic events; (10) Solventum’s business dealings involving third-party partners in various markets; (11) Solventum’s ability to access the capital and credit markets and changes in Solventum’s credit ratings; (12) exposure to interest rate and currency risks; (13) the highly competitive environment in which Solventum operates and consolidation in the healthcare industry; (14) reduction in customers’ research budgets or government funding; (15) the timing and market acceptance of Solventum’s new product and service offerings; (16) ongoing working relationships with certain key healthcare professionals; (17) changes in reimbursement practices of governments or private payers or³ other cost containment measures; (18) Solventum’s ability to obtain components or raw materials supplied by third parties and other manufacturing and related supply chain difficulties, interruptions and disruptive factors; (19) legal and regulatory proceedings and legal compliance risks (including third-party risks) with regards to antitrust, FCPA and other anti-bribery laws, environmental laws, anti-kickback and false claims laws, privacy laws, product liability claims, tax laws, and other laws and regulations in the United States and other countries in which Solventum operates; (20) potential liabilities related to per-and polyfluoroalkyl substances, collectively known as “PFAS”; (21) risks related to the highly regulated environment in which Solventum operates; (22) risks associated with product liability claims; (23) climate change and measures to address climate change; (24) security breaches and other disruptions to information technology infrastructure; (25) artificial intelligence risks; (26) Solventum’s failure to obtain, maintain, protect or effectively enforce its intellectual property rights; (27) pension and postretirement obligation liabilities; (28) Solventum's separation from 3M and performance as a standalone company, including the tax-free nature of the spin and its ability to execute on its short- and long-range plans and capital allocation strategies; and (29) restructuring programs, and other risks and uncertainties described in Solventum’s filings with the U.S. Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q.

The above list is not exhaustive or necessarily set forth in the order of importance. Forward-looking statements are based on certain assumptions and expectations of future events and trends, and actual future results and trends may differ materially from historical results or those reflected in any such forward-looking statements depending on a variety of factors. A further description of these factors is located under “Cautionary Note Concerning Forward-Looking Statements” and “Risk Factors” in Solventum’s periodic reports on file with the U.S. Securities & Exchange Commission. Solventum assumes no obligation to update any forward-looking statements discussed herein as a result of new information, future events or otherwise, except as required by applicable law.

Non-GAAP Financial Measures... (truncated)ors understand our underlying business performance and Solventum uses these measures as an indication of the strength of Solventum and its ability to generate cash.

Solventum calculates forward-looking non-GAAP financial measures, including organic sales growth, adjusted gross margin, adjusted operating income, adjusted operating income margin, adjusted effective tax rate, adjusted diluted earnings per share and free cash flow based on internal forecasts that omit certain amounts that would be included in GAAP financial measures. Solventum does not provide reconciliations of these forward-looking non-GAAP financial measures to the most directly comparable GAAP measures as it is unable to predict with reasonable certainty and without unreasonable effort certain items such as the impact of changes in currency exchange rates, impacts associated with business acquisitions or divestitures, and the timing and magnitude of restructuring activities, among other items. The timing and amounts of these items are uncertain and could have a material impact on Solventum’s results in accordance with GAAP.

The Q2 2026 financial statements and financial information, including reconciliations of non-GAAP financial measures, are available on Solventum’s website: investors.solventum.com.

About Solventum

At Solventum, we enable better, smarter, safer healthcare to improve lives. As a new company with a long legacy of creating breakthrough solutions for our customers' toughest challenges, we pioneer game-changing innovations at the intersection of health, material and data science that change patients’ lives for the better — while empowering healthcare professionals to perform at their best. See how at Solventum.com.

Solventum Investor Contact: investors@solventum.com

Solventum Media Contact: news@solventum.com⁴

## Financial statements

### Income Statement (Three months ended June 30, — Second Quarter and First Six Months 2026 Financial Results (Dollars in millions, except per share amounts))

| | Three months ended June 30, – 2026 | Three months ended June 30, – 2025 | Three months ended June 30, – Year-over-year change | Six Months Ended June 30, – 2026 | Six Months Ended June 30, – 2025 | Six Months Ended June 30, – Year over year change |
|---|---:|---:|---:|---:|---:|---:|
| Net sales | 2,209 | 2,161 | 2.2 | 4,216 | 4,231 | -0.4 |
| Selling, general and administrative expenses | 927 | 772 | 20.1 | 1,754 | 1,541 | 13.8 |
| Research and development expenses | 178 | 189 | -5.8 | 367 | 381 | -3.7 |
| Operating income margin | 8.2% | 9.9% | (170) bps | 6.2% | 8.7% | (250) bps |
| Adjusted operating income margin1 | 28.4% | 21.9% | 650 bps | 24.2% | 20.8% | 340 bps |
| Net income | 92 | 90 | 2.2 | 105 | 227 | -53.7 |
| Diluted earnings per share | 0.53 | 0.51 | 3.9 | 0.6 | 1.3 | -53.8 |
| Adjusted diluted earnings per share1 | 2.55 | 1.69 | 50.9 | 4.02 | 3.03 | 32.7 |
| Net cash provided by (used in) operating activities | 227 | 169 | 34.3 | 38 | 198 | -80.8 |
| Free cash flow1 | 144 | 59 | 144.1 | -129 | -21 | -514.3 |

### Income Statement (Three months ended June 30, — (Unaudited))

| | Three months ended June 30, – 2026 | Three months ended June 30, – 2025 | Six months ended June 30, – 2026 | Six months ended June 30, – 2025 |
|---|---:|---:|---:|---:|
| Net sales of product | 1,698 | 1,668 | 3,211 | 3,265 |
| Net sales of software and rentals | 511 | 493 | 1,005 | 966 |
| Total net sales | 2,209 | 2,161 | 4,216 | 4,231 |
| Cost of product | 807 | 865 | 1,603 | 1,700 |
| Cost of software and rentals | 116 | 121 | 231 | 242 |
| Gross profit | 1,286 | 1,175 | 2,382 | 2,289 |
| Selling, general and administrative expenses | 927 | 772 | 1,754 | 1,541 |
| Research and development expenses | 178 | 189 | 367 | 381 |
| Operating income | 181 | 214 | 262 | 367 |
| Interest expense, net | 64 | 103 | 125 | 207 |
| Other expense (income), net | 9 | 8 | 13 | 19 |
| Income before income taxes | 108 | 103 | 123 | 141 |
| Provision for (benefit from) income taxes | 15 | 13 | 19 | -86 |
| Net income | 92 | 90 | 105 | 227 |
| Earnings per share: | Basic earnings per share | 0.53 | 0.52 | 0.6 | 1.31 |
| Earnings per share: | Diluted earnings per share | 0.53 | 0.51 | 0.6 | 1.3 |
| Weighted-average number of shares outstanding: | Basic | 172.7 | 174.1 | 173.5 | 173.9 |
| Weighted-average number of shares outstanding: | Diluted | 173.3 | 175.2 | 174.4 | 175 |

### Income Statement

| | BUSINESS SEGMENT INFORMATION AND DISAGGREGATED NET SALES* – Three months ended June 30, 2026 – Net sales | BUSINESS SEGMENT INFORMATION AND DISAGGREGATED NET SALES* – Three months ended June 30, 2026 – Operating income | BUSINESS SEGMENT INFORMATION AND DISAGGREGATED NET SALES* – Three months ended June 30, 2026 – Operating margin % | Three months ended June 30, 2025 – Net sales | Three months ended June 30, 2025 – Operating income | Three months ended June 30, 2025 – Operating margin % |
|---|---:|---:|---:|---:|---:|---:|
| Advanced Wound Care | 537 |  |  | 467 |  |  |
| Infection Prevention and Surgical Solutions | 836 |  |  | 750 |  |  |
| MedSurg | 1,372 | 355 | 25.8% | 1,218 | 210 | 17.3% |
| Dental Solutions | 396 | 131 | 33.0% | 338 | 96 | 28.5% |
| Health Information Systems | 354 | 145 | 41.0% | 339 | 120 | 35.5% |
| Total reportable segment net sales and operating income | 2,122 | 631 |  | 1,895 | 426 |  |
| Purification and Filtration |  |  | NM | 189 | 43 | 23.1% |
| All Other | 87 | 19 | 21.4% | 77 | 8 | 10.3% |
| Amortization expense |  | -90 |  |  | -78 |  |
| Corporate and unallocated |  | -378 |  |  | -185 |  |
| Total Company | 2,209 | 181 | 8.2% | 2,161 | 214 | 9.9% |

### Income Statement ((Unaudited))

| | BUSINESS SEGMENT INFORMATION AND DISAGGREGATED NET SALES* – Six months ended June 30, 2026 – Net sales | BUSINESS SEGMENT INFORMATION AND DISAGGREGATED NET SALES* – Six months ended June 30, 2026 – Operating income | BUSINESS SEGMENT INFORMATION AND DISAGGREGATED NET SALES* – Six months ended June 30, 2026 – Operating margin % | Six months ended June 30, 2025 – Net sales | Six months ended June 30, 2025 – Operating income | Six months ended June 30, 2025 – Operating margin % |
|---|---:|---:|---:|---:|---:|---:|
| Advanced Wound Care | 1,034 |  |  | 915 |  |  |
| Infection Prevention and Surgical Solutions | 1,573 |  |  | 1,460 |  |  |
| MedSurg | 2,607 | 516 | 19.8% | 2,375 | 416 | 17.5% |
| Dental Solutions | 750 | 218 | 29.0% | 667 | 175 | 26.2% |
| Health Information Systems | 696 | 276 | 39.6% | 667 | 229 | 34.3% |
| Total reportable segment net sales and operating income | 4,053 | 1,009 |  | 3,709 | 820 |  |
| Purification and Filtration |  |  | NM | 369 | 70 | 19.2% |
| All Other | 163 | 30 | 18.6% | 153 | 19 | 12.7% |
| Amortization expense |  | -181 |  |  | -159 |  |
| Corporate and unallocated |  | -597 |  |  | -384 |  |
| Total Company | 4,216 | 262 | 6.2% | 4,231 | 367 | 8.7% |

### Balance Sheet (December 31, — (Unaudited))

| | June 30, – 2026 | December 31, – 2025 |
|---|---:|---:|
| Current assets | Cash and cash equivalents | 403 | 878 |
| Current assets | Accounts receivable — net of allowances of $82 and $87 | 1,310 | 1,034 |
| Current assets | Due from related parties | 122 | 150 |
| Inventories | Finished goods | 573 | 636 |
| Inventories | Work in process | 218 | 201 |
| Inventories | Raw materials and supplies | 249 | 229 |
| Inventories | Total inventories | 1,040 | 1,066 |
| Inventories | Other current assets | 865 | 731 |
| Inventories | Total current assets | 3,741 | 3,859 |
| Inventories | Property, plant and equipment — net | 1,565 | 1,326 |
| Inventories | Goodwill | 5,626 | 5,704 |
| Inventories | Intangible assets — net | 2,408 | 2,592 |
| Inventories | Other assets | 904 | 814 |
| Inventories | Total assets | 14,243 | 14,294 |
| Current liabilities | Short-term borrowings and current portion of long-term debt | 506 |  |
| Current liabilities | Accounts payable | 701 | 687 |
| Current liabilities | Due to related parties | 331 | 435 |
| Current liabilities | Unearned revenue | 596 | 621 |
| Current liabilities | Other current liabilities | 1,528 | 1,393 |
| Current liabilities | Total current liabilities | 3,663 | 3,136 |
| Current liabilities | Long-term debt | 4,573 | 5,035 |

### Cash Flow (Six months ended June 30, — (Unaudited))

| | Six months ended June 30, – 2026 | Six months ended June 30, – 2025 |
|---|---:|---:|
| Cash flows from operating activities | Net income | 105 | 227 |
| Adjustments to reconcile net income to net cash provided by (used in) operating activities | Depreciation and amortization | 268 | 251 |
| Adjustments to reconcile net income to net cash provided by (used in) operating activities | Pension and postretirement benefit expense | 27 | 32 |
| Adjustments to reconcile net income to net cash provided by (used in) operating activities | Stock-based compensation expense | 89 | 83 |
| Adjustments to reconcile net income to net cash provided by (used in) operating activities | Deferred income taxes | -88 | -177 |
| Changes in assets and liabilities | Accounts receivable | -286 | -15 |
| Changes in assets and liabilities | Due from related parties | 27 | 4 |
| Changes in assets and liabilities | Inventories | 18 | -77 |
| Changes in assets and liabilities | Accounts payable | 26 | 23 |
| Changes in assets and liabilities | Due to related parties | -117 | -6 |
| Changes in assets and liabilities | Accrued compensation | -101 | -47 |
| Changes in assets and liabilities | All other operating activities — net | 68 | -100 |
| Changes in assets and liabilities | Net cash provided by operating activities | 38 | 198 |
| Cash flows from investing activities | Purchases of property, plant and equipment | -167 | -219 |
| Cash flows from investing activities | Other — net | 3 | -5 |
| Cash flows from investing activities | Net cash used in investing activities | -164 | -224 |
| Cash flows from financing activities | Repayment of debt |  | -200 |
| Cash flows from financing activities | Proceeds from debt, net of issuance costs | 46 |  |
| Cash flows from financing activities | Net transfers from (to) 3M | 2 | -30 |
| Cash flows from financing activities | Purchases of treasury stock | -355 |  |
| Cash flows from financing activities | Other — net | -44 | -19 |
| Cash flows from financing activities | Net cash used in financing activities | -350 | -249 |
| Cash flows from financing activities | Effect of exchange rate changes on cash and cash equivalents | 1 | 7 |
| Cash flows from financing activities | Net increase (decrease) in cash and cash equivalents | -475 | -268 |
| Cash flows from financing activities | Cash and cash equivalents at beginning of period | 878 | 762 |
| Cash flows from financing activities | Less: Cash and cash equivalents within held for sale |  | -2 |
| Cash flows from financing activities | Cash and cash equivalents at end of period | 403 | 492 |

### Cash Flow (Three months ended June 30, (in millions))

| | Three months ended June 30, – 2026 | Three months ended June 30, – 2025 | Six months ended June 30, – 2026 | Six months ended June 30, – 2025 |
|---|---:|---:|---:|---:|
| Net cash provided by operating activities | 227 | 169 | 38 | 198 |
| Net cash used in investing activities | -87 | -110 | -164 | -224 |
| Net cash used in financing activities | -300 | -110 | -350 | -249 |
| Free cash flow (non-GAAP measure) | Net cash provided by operating activities | 227 | 169 | 38 | 198 |
| Free cash flow (non-GAAP measure) | Purchases of property, plant and equipment | -83 | -110 | -167 | -219 |
| Free cash flow (non-GAAP measure) | Free cash flow | 144 | 59 | -129 | -21 |
